|
|
Lenvatinib is a targeted therapy medication used primarily in the treatment of Hepatocellular Carcinoma (HCC), which is the most common type of primary liver cancer. Unlike traditional chemotherapy, which attacks all rapidly dividing cells, Lenvatinib is a multikinase inhibitor. It works by blocking specific proteins (kinases) on the surface of cancer cells and the surrounding blood vessels, effectively "starving" the tumor of the nutrients and oxygen it needs to grow.
Clinical Use and Dosage
In the context of liver cancer, Lenvaxen 10 Mg (Lenvatinib) is typically prescribed as a first-line treatment for patients whose tumors cannot be removed by surgery (unresectable HCC).
The dosage is determined based on the patient's body weight to ensure efficacy while managing potential toxicity:
For patients weighing 60 kg (approx. 132 lbs) or more: The standard starting dose is 12 mg once daily.
For patients weighing less than 60 kg: The standard starting dose is 8 mg once daily.
The medication is available in 10 mg and 4 mg capsules. This allows healthcare providers to reach the precise weight-based dosage (e.g., two 4 mg capsules for an 8 mg dose, or one 10 mg and one 4 mg for a 14 mg adjusted dose) and to make incremental adjustments if side effects occur.
How Lenvatinib Works
Lenvatinib targets several pathways involved in the progression of liver cancer:
VEGFR (Vascular Endothelial Growth Factor Receptor): This is the primary target. By blocking these receptors, the drug inhibits angiogenesis—the process by which tumors create new blood vessels.
FGFR (Fibroblast Growth Factor Receptor): This pathway is often overactive in liver cancer, contributing to tumor cell proliferation.
PDGFRα, KIT, and RET: These additional targets further inhibit the signaling pathways that allow cancer cells to divide and survive.
By simultaneously hitting these multiple targets, Lenvatinib can slow down tumor growth and, in many cases, cause tumors to shrink.
Key Considerations and Side Effects
While effective, Lenvatinib is a potent medication that requires close monitoring by an oncology team.
Common Side Effects:
Hypertension (High Blood Pressure): This is the most frequent side effect. Patients are often required to monitor their blood pressure daily at home.
Fatigue and Weakness: Many patients experience significant tiredness.
Decreased Appetite and Weight Loss: Monitoring nutritional intake is vital during treatment.
Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome): Redness, swelling, and pain on the palms of the hands and soles of the feet.
Gastrointestinal Issues: Including diarrhea, nausea, and abdominal pain.
Serious Risks:
In rare cases, Lenvatinib can cause more severe complications such as liver toxicity, kidney failure, or cardiac dysfunction. Blood tests and physical exams are performed regularly to ensure the patient’s organs are handling the medication safely.
Conclusion
Lenvatinib represents a significant advancement in the treatment of advanced liver cancer. By focusing on the weight-based administration of 10 mg and 4 mg capsules, doctors can provide a tailored approach to managing the disease. It is important for patients to take the medication exactly as prescribed—usually at the same time every day, with or without food—and to report any new symptoms to their medical team immediately.
|
|
发表于